Jim Fitzsimmons, President and Chief Executive Officer
Jim joined TRS in March, 2010, and has over 30 years of experience in the medical device industry. He has been involved with start-up medical device companies for the last 21 years backed by prestigious venture capital firms such as MPM Capital, InterWest Partners and Kleiner Perkins Caufield and Byers. Prior to TRS, Jim was Chairman and Chief executive Officer of Archus Orthopedics, Inc., which was acquired in 2009. Archus was one of three companies created by Scout Medical Technologies LLC, a medical device incubation firm that Jim founded in 2000 and led as Managing Director. In association with his work at Scout, in addition to Archus Orthopedics, Jim co-founded and continues as a Board member of Cardiac Dimensions, Inc., and co-founded EndoGastric Solutions, Inc., both successful start-up medical device companies. Prior to Scout, Jim served as Senior Vice President and General Manager of Guidant Corporation's Cardiac and Vascular Surgery Group. He joined Guidant in 1997 as a result of its acquisition of EndoVascular Technologies ("EVT"). Jim was President and Chief Executive Officer of EVT for six years prior to the Guidant acquisition, taking the company public in 1996. Before that, Jim spent eleven years with the Medical Device and Diagnostic Division of Eli Lilly and Company. During his tenure at Lilly, Jim held a variety of positions in sales, marketing, mergers and acquisitions, and general management. Jim currently serves on the Board of Directors of RF Surgical Systems, Inc., a privately held medical device company. He previously served as Chairman of the Board of Directors of VNUS Medical Technologies, Inc., a publicly traded medical device company sold to Covidien in 2009, and as a member of the Board of Directors of AsthmatX, Inc., a privately held medical device company sold to Boston Scientific in 2010. He also serves on the Advisory Board of the Albers School of Business Innovation and Entrepreneurship Center at Seattle University. Jim holds a B.S. in Biology-Premedical and a MBA from Seattle University.
Jim Adox, Chairman of the Board
Jim, a TRS co-founder, is a Managing Director at Venture Investors, LLC ("VI"), a Midwest venture capital firm specializing in seed and early stage healthcare and technology investments. He joined VI in 2007 and heads up their Ann Arbor, Michigan office. Jim's prior venture capital experience includes a combined nine years as a partner at RidgeLine Ventures and EDF Ventures, where he led the spin-out, sourcing, financing, syndication and exit of numerous investments. During this time, he served as President, CFO, and COO of select companies until a management team was recruited. Jim previously served on the Boards of Directors of Avail Networks (acquired by ERI) and HandyLab (acquired by BD), and as an observer for Alfalight, Ardesta, TherOx and Xtera Communications. He currently serves on the Boards of Directors of HistoSonics, Incept BioSystems, and the Michigan Venture Capital Association. Prior to his venture capital positions, Jim had nine years of corporate operating experience in marketing, engineering, business development and operations. Outside of his VI responsibilities, Jim is on the Board of Advisors to the Frankel Commercialization Fund, The Medical Innovations Center, Tech Arb, and Huron River Ventures. Jim earned a B.S. in Mechanical Engineering, an M.S. in Mechanical Engineering and a MBA with High Distinction, all from the University of Michigan.
Hank Brown, Board Member
Hank, a TRS investor, has over 25 years of experience in medical device sales, marketing, distribution and general management. As an entrepreneur and investor, Hank has provided fiscal, strategic and operations leadership to multiple companies in the medical device industry. Together with his brother Richard, Hank developed and implemented a plan to restructure and recapitalize Rogue Inc., a medical logistics company, successfully turning the company around and more than tripling sales in the first five years. Hank has founded two successful medical device distributorships. The recent sale of one of these operations to Johnson & Johnson has given Hank more time to devote to new business development opportunities. Hank is a member of the Board of Directors, and was a founding investor and interim CEO of Tangent Medical Technologies, a University of Michigan technology spin-out. In addition to his Board roles with Tangent and TRS, Hank serves on the Board of Micro-Machine, an orthopaedic manufacturing company backed by a private equity group also based in Ann Arbor. Hank has also been involved as a Board member of FOCOS, a non-profit organization dedicated to helping underprivileged children in the developing world who need musculoskeletal care.
Frank La Marca, M.D., Founder and Board Member
Frank, a TRS co-founder, is a Clinical Assistant Professor in the Department of Orthopedics, and Director of the Surgical Spine Program in the Department of Neurosurgery at the University of Michigan School of Medicine. He is also Co-Director of the Spine Lab, a joint endeavor between the Departments of Neurosurgery and Biomedical Engineering at Michigan. Frank received his M.D. at Catholic University Medical School in Rome, Italy in 1993, and completed his Residency in Neurosurgery in 1996. He completed a Fellowship in Pediatric Neurosurgery at Children's Memorial Hospital, Chicago, Illinois in 1997. He then completed a Residency in Neurosurgery and a Fellowship in Complex and Reconstructive Spinal Surgery at Northwestern University in 2003. In 2004 Frank moved to the University of Michigan. Frank has published 24 manuscripts and received numerous honors. He has also received funding for a variety of research projects from DePuy Spine and Stryker Corporation.
William L. Murphy, Ph.D., Founder and Board Member
Bill is an Associate Professor of Biomedical Engineering as well as Orthopedics and Rehabilitation at the University of Wisconsin. He received his Ph.D. in Biomedical Engineering from the University of Michigan in 2002, and was a postdoctoral fellow in Chemistry at the University of Chicago from 2002-2004. Bill's research interests focus on designing "bio-inspired" materials that mimic and exploit biological systems. Applications include activated implants for bone regeneration and autologous tissue engineering. He has published over 60 manuscripts, 10 book chapters, and 15 patents. He has also received several honors and holds numerous advisory positions, including the editorial boards of Acta Biomaterialia and Advanced Functional Materials.
Stephen E. Feinberg, D.D.S, MS, Ph.D., Founder
Steve is a board-certified oral and maxillofacial surgeon and Professor in the Department of Oral and Maxillofacial Surgery at the University of Michigan School of Medicine. Additionally, he is a Professor in the Department of Oral and Maxillofacial Surgery at the University of Michigan. Steve serves on the Editorial Board of the International Journal of Oral and Maxillofacial Surgery and is Chairman of the Section on Research and Emerging Technologies. He is currently Chairman of the Research Committee for the International Association of Oral and Maxillofacial Surgery and past Chairman of the Advisory Committee on Research Planning and Technology Assessment for the American Association of Oral and Maxillofacial Surgery. In addition, Steve served on the Biotechnology Advisory Boards of the AO Foundation and Davos Switzerland, and on the Scientific Advisory Board of the REGEA Institute of Regenerative Medicine in Tampere, Finland. Steve was the recipient of the 1976 Association of Oral and Maxillofacial Surgery Research Fellowship and the 2004 recipient of the Oral and Maxillofacial Surgery Foundation Research Recognition Award. He is the author of numerous publications and internationally recognized for his contributions to temporomandibular joint surgery and reconstruction.
Scott J. Hollister, Ph.D., Founder
Scott, a TRS co-founder, is a Professor in the Departments of Biomedical Engineering and Mechanical Engineering, and an Associate Professor in the Department of Surgery at the University of Michigan. He has published 90 peer reviewed papers, 22 book chapters, and has been invited to give over 65 presentations in his career. He also is an inventor on 4 issued patents. Scott's main research interest is the design, manufacture and characterization of three dimensional biomaterial platform systems for skeletal tissue (bone and cartilage) reconstruction. Scott collaborates with a number of clinicians on development of pre-clinical animal models to test these biomaterial platform systems for Craniomaxillofacial, Spine, and Orthopedic applications. His work has been funded by the National Institutes of Health and noted in the New York Times. In addition to his work on scaffold development, Scott also works in the area of computational surgical planning, helping to develop surgical plans and models for skeletal defect reconstruction in human patients. Scott is a fellow of the American Institute for Medical and Biological Engineering and has received numerous awards and honors during his career.